SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Singleton who wrote (5089)8/6/1998 2:23:00 PM
From: Pseudo Biologist  Read Replies (1) of 6136
 
Re: Antisense rights (maybe relevant to general "small molecule rights" in the future)

Peter, the antisense rights usually claimed by the genomicists are specific to the target. I think, correct me if I am wrong, that much of Isis patent estate refers to enabling technology to make antisense work pretty much regardless of target. This would be the case for new chemistries and/or technology to improve cell penetration.

My guess is that if company "A" wants to make an antisense to gene X, patented by, say, Incyte, they may need a license from INCY, and another from Isis if they use their chemistries. I see these kinds of patents as complementary rather than directly competitive.

This does not mean Incyte would not try to sue Isis if the latter developed an antisense agent, using whatever chemistry, to one of Incyte's genes (a la Chiron vs. Agouron, Gilead, ...)

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News